Ledasorexton

Ledasorexton
Clinical data
Other namesE-2086; E2086
Routes of
administration		Oral
Drug classOrexin OX2 receptor agonist; Wakefulness-promoting agent
Identifiers
  • (2R)-2-cyclopropyl-2-[(1S,5R)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H32FN5O2
Molar mass417.529 g·mol−1
3D model (JSmol)
  • CO[C@@H]1CN(CC[C@@H]1C2C[C@H]3CC[C@@H](C2)N3[C@H](C4CC4)C(=O)N)C5=NC=C(C=N5)F
  • InChI=1S/C22H32FN5O2/c1-30-19-12-27(22-25-10-15(23)11-26-22)7-6-18(19)14-8-16-4-5-17(9-14)28(16)20(21(24)29)13-2-3-13/h10-11,13-14,16-20H,2-9,12H2,1H3,(H2,24,29)/t14?,16-,17+,18-,19-,20-/m1/s1
  • Key:AXOUSJFGEOVDQT-GFVFYWETSA-N

Ledasorexton (INNTooltip International Nonproprietary Name; developmental code name E-2086) is a selective orexin OX2 receptor agonist which is under development for the treatment of narcolepsy. It is taken orally. The drug is under development by Eisai. As of May 2026, it is in phase 2 clinical trials for narcolepsy.

See also

References

  1. 1 2 3 4 5 "Ledasorexton". AdisInsight. 27 May 2026. Retrieved 5 June 2026.
  2. 1 2 3 "Delving into the Latest Updates on Ledasorexton with Synapse". Synapse. 23 May 2026. Retrieved 5 June 2026.